Swedish Orphan Biovitrum Becomes Market Authorisation Holder For Xiapex In Europe

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on 3 April, 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news